Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts.

Author: AlessandriElisa, BrizzolaraRenata, CutoloMaurizio, MontagnaPaola, PizzorniCarmen, SmithVanessa, SoldanoStefano, SulliAlberto, TavillaPietro Paolo, VillaggioBarbara

Paper Details 
Original Abstract of the Article :
OBJECTIVE: To investigate the effects of the endothelin 1 (ET-1) receptor antagonists (ETRA) macitentan, its active metabolite ACT-132577, and bosentan on myofibroblast activation and extracellular matrix production induced by ET-1 in cultured systemic sclerosis (SSc) and control skin fibroblasts. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.3899/jrheum.141070

データ提供:米国国立医学図書館(NLM)

Macitentan: A Potential New Weapon Against Systemic Sclerosis

Systemic sclerosis (SSc), a debilitating autoimmune disease, is a formidable foe, causing widespread fibrosis and damage to various organs. This study investigates the potential of macitentan, an endothelin receptor antagonist (ETRA), to combat the fibrosis associated with SSc. It's like discovering a new antidote for a poisonous desert plant, offering hope for a healthier and more fulfilling life for those affected by SSc. The researchers investigated the effects of macitentan, its active metabolite ACT-132577, and bosentan on cultured human SSc and control skin fibroblasts.

Macitentan's Potential Benefits

The study found that macitentan and ACT-132577 significantly reduced the expression of α-smooth muscle actin (α-SMA), a marker of myofibroblast activation and fibrosis. It's like uncovering a hidden oasis in the desert, a source of relief from the harsh effects of SSc. They also observed a reduction in the synthesis of type I collagen and fibronectin, key components of the extracellular matrix that contributes to fibrosis. The researchers concluded that macitentan and its active metabolite have a potential therapeutic role in SSc by inhibiting myofibroblast activation and fibrosis.

A Promising New Avenue for SSc Treatment

This study provides encouraging evidence for the potential therapeutic role of macitentan in SSc. It's a reminder that even in the vast and challenging landscape of medicine, new discoveries and treatments are always emerging. Further research is needed to confirm these findings and evaluate the safety and efficacy of macitentan in human patients.

Dr. Camel's Conclusion

This research offers a glimmer of hope for those struggling with systemic sclerosis. Macitentan shows promise as a potential therapeutic agent for this debilitating disease, offering the potential to slow or even reverse the fibrosis that characterizes SSc. It's a journey through the desert of medicine, where we must always be optimistic and persevere in our search for new and effective treatments.

Date :
  1. Date Completed 2016-03-24
  2. Date Revised 2019-09-17
Further Info :

Pubmed ID

25593238

DOI: Digital Object Identifier

10.3899/jrheum.141070

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.